⚕️ Education, not medical advice
This course surveys experimental and frontier longevity interventions for general understanding. NONE of it is medical advice or a recommendation to take any drug, compound, or therapy. Most interventions here are unproven in healthy humans and carry real risks — anything you'd consider belongs in the hands of a qualified clinician.
If you could clear out the damaged 'zombie' cells that accumulate with age, could you turn back aspects of aging itself? That's the electrifying premise behind senolytics — one of the most promising and actively researched new classes of longevity interventions. Here's the science and the honest status.
Learning Objectives
- •Recall why senescent cells drive aging
- •Understand senolytics and senomorphics
- •Assess the current evidence honestly
Recap: senescent cells drive aging
From the Hallmarks course: SENESCENT cells are damaged cells that stop dividing but refuse to die, accumulating with age and secreting an inflammatory cocktail (the SASP) that damages surrounding tissue and spreads dysfunction. In animal studies, simply CLEARING these cells improved function and extended healthy lifespan — establishing them as a genuine CAUSE of aging, not just a marker. That result launched a whole therapeutic strategy.
Senolytics: clearing the zombie cells
SENOLYTICS are compounds that selectively KILL senescent cells (exploiting their resistance to normal cell death). Leading examples in research include the combination of dasatinib and quercetin (D+Q) and the natural flavonoid fisetin. A notable feature is 'HIT AND RUN' dosing — because senescent cells accumulate slowly, senolytics may work given INTERMITTENTLY (e.g. a few days periodically) rather than continuously, potentially reducing side effects.
Senomorphics: muting the SASP
A complementary strategy is SENOMORPHICS — compounds that don't kill senescent cells but SUPPRESS their harmful SASP secretions, muting the damage they cause. Each approach has trade-offs: senolytics remove the problem cells (but killing cells has risks), while senomorphics quiet them (but the cells remain and must be treated continuously). Both are active areas of research.
The honest status
Senolytics are among the most PROMISING frontier interventions — the animal data are genuinely impressive, and human trials are underway (for conditions like osteoarthritis, lung fibrosis, and frailty). But it's still EARLY: human efficacy and long-term safety aren't established, and clearing cells indiscriminately could have downsides. This is a class to watch closely and take seriously — but not yet a proven therapy to adopt.
Why 'hit and run' dosing is a clever feature
Most drugs must be taken continuously, accumulating side-effect risk. Senolytics may be different: since senescent cells build up gradually, a short periodic course could clear them and then stop until they re-accumulate — 'hit and run'. If it holds up in humans, this intermittent dosing could make senolytics safer and more practical than continuous drugs, which is part of why the class generates so much excitement.
Senolytics, by the numbers
- ▸Senescent cells accumulate with age and drive damage via the inflammatory SASP
- ▸Senolytics selectively kill senescent cells (e.g. dasatinib+quercetin, fisetin)
- ▸'Hit and run' intermittent dosing may suit them, potentially reducing side effects
- ▸Senomorphics instead mute the SASP; both are promising but early in humans
Senolytics are a proven, available therapy to reverse aging.
Senolytics are among the most promising frontier classes, with impressive animal data and human trials underway — but they're early-stage, with human efficacy and long-term safety not yet established. Promising science to watch, not a proven therapy to adopt.
Quick Check
What do senolytics do?
Quick Check
Why might 'hit and run' intermittent dosing suit senolytics?
True or False
Clearing senescent cells in animal studies improved function and extended healthy lifespan.
Summary
- →Senescent cells drive aging via the inflammatory SASP
- →Senolytics selectively kill them (e.g. dasatinib+quercetin, fisetin), possibly via 'hit and run' dosing
- →Senomorphics instead suppress the SASP
- →Among the most promising frontier classes — impressive in animals, still early in humans
The most radical frontier aims not to clear damaged cells but to REGENERATE and reset them. Next: regenerative and cellular approaches.